Cancer Research Technology
Log in Register
Menu

Caki-2 SETD2 KO cell line

Invented by Sergio F de Almeida
Invented at Instituto de Medicina Molecular João Lobo Antunes

Info

Catalogue Number 160724
Antigen/Gene or Protein Targets SET domain containing 2
Parental Line Clear cell renal cell carcinoma cell line (Caki-2)
Synonyms HBP231, HIF-1, HIP-1, HYPB, KMT3A
Host Human
Tissue Kidney
Model Cancer Model
Relevance Experimental ablation of SETD2 gene expression using the CRISPR/Cas9 system renders Caki-2-SETD2 knockout cells a valuable tool to investigate the role of H3K36me3 histone methylation in processes such as transcription or DNA repair.
Production Details CRISPR/Cas9 KO
Conditional No
Research Area Cancer, DNA Damage and Repair, Epigenetics & Nuclear Signalling, Gene Expression
Recommended Growing Conditions Grow as monolayers in Dulbecco’s modified Eagle medium, supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/mL penicillin-streptomycin, at 37 °C in a humidified atmosphere with 5% CO2.
Notes Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.

This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

de Matos et al. 2019. Cancers (Basel). 11(3):. PMID: 30897760.


Add a reference

References: 1 entry

de Matos et al. 2019. Cancers (Basel). 11(3):. PMID: 30897760.


Add a reference

Inventor Information